Arteriosclerosis, Vol 6, 178-188, Copyright © 1986 by American Heart Association

ARTICLES

Conservation of the low density lipoprotein receptor-binding domain of apoprotein B. Demonstration by a new monoclonal antibody, MB47

SG Young, JL Witztum, DC Casal, LK Curtiss and S Bernstein

The fact that low density lipoprotein (LDL) from multiple animal species binds to the human LDL receptor suggested that the LDL-receptor binding domain of apoprotein (apo)B must be evolutionarily conserved. To determine if a common receptor domain epitope existed on apo B, we generated a monoclonal antibody that was specific for the LDL-receptor domain of apo B. This was accomplished by using a screening procedure that selected for a hybridoma supernatant that could block specific cellular uptake and degradation of LDL. Western blots showed that this antibody, termed MB47, was specific for apo B-100. Fluid phase assays indicated a high binding affinity (Ka = 4 X 10(9) M-1) and demonstrated that all human LDL particles expressed the MB47 epitope. Scatchard analysis indicated that a maximum of one MB47 molecule bound to each LDL particle. In solid phase assays, antibody MB47 bound to plasma or LDL of multiple mammalian species, including guinea pig, rabbit, pig, dog, cat, seal, whale, bear, and lion, but it did not bind to mouse or rat LDL. In contrast, a rabbit antiserum to LDL and two other anti-apo B monoclonal antibodies, MB3 and MB19, which do not bind to the receptor domain, were specific only for human LDL. LDL from multiple species, including mouse LDL, competed effectively with 125I-human LDL for binding to human fibroblasts. MB47 effectively inhibited uptake and degradation of labeled human, guinea pig, and rabbit LDL by both human and guinea pig fibroblasts. We conclude that antibody MB47 binds to a single receptor domain on LDL and identifies a vital region conserved through mammalian evolution.

This article has been cited by other articles:

				Y.-T. Wang, A. von Zychlinski, and S. P. A. McCormick Dimyristoylphosphotidylcholine induces conformational changes in apoB that lowers lipoprotein(a) J. Lipid Res., May 1, 2009; 50(5): 846 - 853. [Abstract] [Full Text] [PDF]

				S. Tsimikas, M. Aikawa, F. J. Miller Jr, E. R. Miller, M. Torzewski, S. R. Lentz, C. Bergmark, D. D. Heistad, P. Libby, and J. L. Witztum Increased Plasma Oxidized Phospholipid:Apolipoprotein B-100 Ratio With Concomitant Depletion of Oxidized Phospholipids From Atherosclerotic Lesions After Dietary Lipid-Lowering: A Potential Biomarker of Early Atherosclerosis Regression Arterioscler Thromb Vasc Biol, January 1, 2007; 27(1): 175 - 181. [Abstract] [Full Text] [PDF]

				C. J. Ng, N. Bourquard, V. Grijalva, S. Hama, D. M. Shih, M. Navab, A. M. Fogelman, A. J. Lusis, S. Young, and S. T. Reddy Paraoxonase-2 Deficiency Aggravates Atherosclerosis in Mice Despite Lower Apolipoprotein-B-containing Lipoproteins: ANTI-ATHEROGENIC ROLE FOR PARAOXONASE-2 J. Biol. Chem., October 6, 2006; 281(40): 29491 - 29500. [Abstract] [Full Text] [PDF]

				T. Yamashita, S. Freigang, C. Eberle, J. Pattison, S. Gupta, C. Napoli, and W. Palinski Maternal Immunization Programs Postnatal Immune Responses and Reduces Atherosclerosis in Offspring Circ. Res., September 29, 2006; 99(7): E51 - E64. [Abstract] [Full Text] [PDF]

				H. Arakawa, J.-Y. Qian, D. Baatar, K. Karasawa, Y. Asada, Y. Sasaguri, E. R. Miller, J. L. Witztum, and H. Ueno Local Expression of Platelet-Activating Factor-Acetylhydrolase Reduces Accumulation of Oxidized Lipoproteins and Inhibits Inflammation, Shear Stress-Induced Thrombosis, and Neointima Formation in Balloon-Injured Carotid Arteries in Nonhyperlipidemic Rabbits Circulation, June 21, 2005; 111(24): 3302 - 3309. [Abstract] [Full Text] [PDF]

				M. Schneider, J. L. Witztum, S. G. Young, E. H. Ludwig, E. R. Miller, S. Tsimikas, L. K. Curtiss, S. M. Marcovina, J. M. Taylor, R. M. Lawn, et al. High-level lipoprotein [a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteins J. Lipid Res., April 1, 2005; 46(4): 769 - 778. [Abstract] [Full Text] [PDF]

				C. A. Reardon, E. R. Miller, L. Blachowicz, J. Lukens, C. J. Binder, J. L. Witztum, and G. S. Getz Autoantibodies to OxLDL fail to alter the clearance of injected OxLDL in apolipoprotein E-deficient mice J. Lipid Res., July 1, 2004; 45(7): 1347 - 1354. [Abstract] [Full Text] [PDF]

				S. Bhakdi, M. Torzewski, K. Paprotka, S. Schmitt, H. Barsoom, P. Suriyaphol, S.-R. Han, K. J. Lackner, and M. Husmann Possible Protective Role for C-Reactive Protein in Atherogenesis: Complement Activation by Modified Lipoproteins Halts Before Detrimental Terminal Sequence Circulation, April 20, 2004; 109(15): 1870 - 1876. [Abstract] [Full Text] [PDF]

				C. Y. Y. Liu, R. Broadhurst, S. M. Marcovina, and S. P. A. McCormick Mutation of lysine residues in apolipoprotein B-100 causes defective lipoprotein[a] formation J. Lipid Res., January 1, 2004; 45(1): 63 - 70. [Abstract] [Full Text] [PDF]

				M. Y. Chang, S. Potter-Perigo, T. N. Wight, and A. Chait Oxidized LDL bind to nonproteoglycan components of smooth muscle extracellular matrices J. Lipid Res., May 1, 2001; 42(5): 824 - 833. [Abstract] [Full Text]

				C. R. Pullinger, D. Gaffney, M. M. Gutierrez, M. J. Malloy, V. N. Schumaker, C. J. Packard, and J. P. Kane The apolipoprotein B R3531C mutation: characteristics of 24 subjects from 9 kindreds J. Lipid Res., February 1, 1999; 40(2): 318 - 327. [Abstract] [Full Text]

				C. H. Zlot, L. M. Flynn, M. M. Véniant, E. Kim, M. Raabe, S. P. A. McCormick, P. Ambroziak, L. M. McEvoy, and S. G. Young Generation of monoclonal antibodies specific for mouse apolipoprotein B-100 in apolipoprotein B-48-only mice J. Lipid Res., January 1, 1999; 40(1): 76 - 84. [Abstract] [Full Text]

				D. A. Sanan, D. L. Newland, R. Tao, S. Marcovina, J. Wang, V. Mooser, R. E. Hammer, and H. H. Hobbs Low density lipoprotein receptor-negative mice expressing human apolipoprotein B-100 develop complex atherosclerotic lesions on a chow diet: No accentuation by apolipoprotein(a) PNAS, April 14, 1998; 95(8): 4544 - 4549. [Abstract] [Full Text] [PDF]

				S. P. A. McCormick, J. K. Ng, C. M. Cham, S. Taylor, S. M. Marcovina, J. P. Segrest, R. E. Hammer, and S. G. Young Transgenic Mice Expressing Human ApoB95 and ApoB97. EVIDENCE THAT SEQUENCES WITHIN THE CARBOXYL-TERMINAL PORTION OF HUMAN apoB100 ARE IMPORTANT FOR THE ASSEMBLY OF LIPOPROTEIN(a) J. Biol. Chem., September 19, 1997; 272(38): 23616 - 23622. [Abstract] [Full Text] [PDF]

				P. Sivaram, T. Vanni-Reyes, and I. J. Goldberg Endothelial Cells Synthesize and Process Apolipoprotein B J. Biol. Chem., June 21, 1996; 271(25): 15261 - 15266. [Abstract] [Full Text] [PDF]

				M. Y. Chang, M. Sasahara, A. Chait, E. W. Raines, and R. Ross Inhibition of Hypercholesterolemia-Induced Atherosclerosis in the Nonhuman Primate by Probucol : II. Cellular Composition and Proliferation Arterioscler Thromb Vasc Biol, October 1, 1995; 15(10): 1631 - 1640. [Abstract] [Full Text]

				W. Palinski, T. Koschinsky, S. W. Butler, E. Miller, H. Vlassara, A. Cerami, and J. L. Witztum Immunological Evidence for the Presence of Advanced Glycosylation End Products in Atherosclerotic Lesions of Euglycemic Rabbits Arterioscler Thromb Vasc Biol, May 1, 1995; 15(5): 571 - 582. [Abstract] [Full Text]

				G. Crepaldi, G. Baggio, M. Arca, G. Avellone, P. Avogaro, G. B. Bon, G. D. Bompiani, A. Capurso, L. Cattin, G. D'Alo, et al. Pravastatin vs Gemfibrozil in the Treatment of Primary Hypercholesterolemia: The Italian Multicenter Pravastatin Study I Arch Intern Med, January 1, 1991; 151(1): 146 - 152. [Abstract] [PDF]

				The Lovastatin Study Group III A Multicenter Comparison of Lovastatin and Cholestyramine Therapy for Severe Primary Hypercholesterolemia JAMA, July 15, 1988; 260(3): 359 - 366. [Abstract] [PDF]

				M. Haberland, D Fong, and L Cheng Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits Science, July 8, 1988; 241(4862): 215 - 218. [Abstract] [PDF]

				R. J. HAVEL, D. B. HUNNINGHAKE, D. R. ILLINGWORTH, R. S. LEES, E. A. STEIN, J. A. TOBERT, S. R. BACON, J. A. BOLOGNESE, P. H. FROST, G. E. LAMKIN, et al. Lovastatin (Mevinolin) in the Treatment of Heterozygous Familial Hypercholesterolemia: A Multicenter Study Ann Intern Med, November 1, 1987; 107(5): 609 - 615. [Abstract] [PDF]

				S. Chen, G Habib, C. Yang, Z. Gu, B. Lee, S. Weng, Silberman SR, S. Cai, J. Deslypere, M Rosseneu, et al. Apolipoprotein B-48 is the product of a messenger RNA with an organ-specific in-frame stop codon Science, October 16, 1987; 238(4825): 363 - 366. [Abstract] [PDF]

				E. J. Cheesman, R. J. Sharp, C. H. Zlot, C. Y.-Y. Liu, S. Taylor, S. M. Marcovina, S. G. Young, and S. P. A. McCormick An Analysis of the Interaction between Mouse Apolipoprotein B100 and Apolipoprotein(a) J. Biol. Chem., September 1, 2000; 275(36): 28195 - 28200. [Abstract] [Full Text] [PDF]

				D. M. Shih, Y.-R. Xia, X.-P. Wang, E. Miller, L. W. Castellani, G. Subbanagounder, H. Cheroutre, K. F. Faull, J. A. Berliner, J. L. Witztum, et al. Combined Serum Paraoxonase Knockout/Apolipoprotein E Knockout Mice Exhibit Increased Lipoprotein Oxidation and Atherosclerosis J. Biol. Chem., June 2, 2000; 275(23): 17527 - 17535. [Abstract] [Full Text] [PDF]